{"id":5874,"date":"2023-06-01T15:16:00","date_gmt":"2023-06-01T15:16:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=5874"},"modified":"2025-01-15T03:03:29","modified_gmt":"2025-01-15T03:03:29","slug":"cost-effectiveness-of-treating-all-hepatitis-b-positive-individuals-in-the-united-states","status":"publish","type":"post","link":"https:\/\/cdafound.org\/fr\/cost-effectiveness-of-treating-all-hepatitis-b-positive-individuals-in-the-united-states\/","title":{"rendered":"Rentabilit\u00e9 du traitement de toutes les personnes s\u00e9ropositives pour l&#039;h\u00e9patite B aux \u00c9tats-Unis"},"content":{"rendered":"<h2 class=\"wp-block-heading\">R\u00e9sum\u00e9<\/h2>\n\n\n\n<p>L&#039;infection chronique par le virus de l&#039;h\u00e9patite B (VHB) est l&#039;une des principales causes de maladie du foie et de mortalit\u00e9 associ\u00e9e dans le monde. Cependant, la plupart des personnes infect\u00e9es aux \u00c9tats-Unis ne sont ni diagnostiqu\u00e9es ni trait\u00e9es. Il est n\u00e9cessaire de comprendre plus compl\u00e8tement l&#039;impact \u00e9conomique et le fardeau de la maladie de la suppression des restrictions de traitement et de l&#039;augmentation du diagnostic et du traitement. Le mod\u00e8le PRoGReSs, un mod\u00e8le dynamique de VHB qui suit la population infect\u00e9e par ann\u00e9e, stade de la maladie et sexe, a \u00e9t\u00e9 utilis\u00e9 pour quantifier la maladie et le fardeau \u00e9conomique de l&#039;infection chronique par le VHB aux \u00c9tats-Unis de 2020 \u00e0 2050 sur la base de quatre sc\u00e9narios\u00a0: un statut sc\u00e9nario de quo (de base) et trois sc\u00e9narios de traitement pour tous, dans lesquels le d\u00e9pistage, le diagnostic et le traitement ont \u00e9t\u00e9 maximis\u00e9s \u00e0 diff\u00e9rents niveaux de prix de traitement annuels de $5382, $2000 et $750. Par rapport au sc\u00e9nario de base, les sc\u00e9narios de traitement pour tous \u00e9viteraient 71 100 cas aigus et 11 100 cas incidents chroniques de VHB, et 169 000 d\u00e9c\u00e8s li\u00e9s au foie de 2020 \u00e0 2050. \u00c0 un co\u00fbt de traitement annuel de $2000, le traitement de toutes les infections \u00e0 VHB serait tr\u00e8s co\u00fbteux -efficace, et \u00e0 $750 serait \u00e9conomique et permettrait d&#039;obtenir un retour sur investissement positif avant 2050. La maximisation de la population VHB diagnostiqu\u00e9e et trait\u00e9e aux \u00c9tats-Unis permettrait d&#039;\u00e9viter un nombre important de cas de maladie h\u00e9patique avanc\u00e9e et de mortalit\u00e9 associ\u00e9e. De telles interventions peuvent \u00e9galement \u00eatre rentables par rapport \u00e0 la strat\u00e9gie du statu quo, et des \u00e9conomies de co\u00fbts \u00e0 un seuil de prix de traitement de $750 par an, au-dessus du co\u00fbt de traitement annuel le plus bas actuel de $362.<\/p>\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link has-text-color wp-element-button\" href=\"https:\/\/cdafound.org\/wp-content\/uploads\/2023\/06\/Razavi-Shearer-2023-HBV-Economic-Impact-Treat-All-US.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Lire le rapport complet<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Summary Chronic hepatitis B virus (HBV) infection is a leading cause of liver disease and related mortality globally. However, most of the infected individuals in the United States remain undiagnosed and untreated. There is a need to understand more completely the economic and disease burden impact of removing treatment restrictions and increasing diagnosis and treatment. [&hellip;]<\/p>\n","protected":false},"author":939,"featured_media":3193,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[32,21,28],"publication-author":[95,80,97,92],"class_list":["post-5874","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-economic-impact","tag-hbv","tag-policy-analysis","publication-author-chris-estes","publication-author-devin-razavi-shearer","publication-author-homie-razavi","publication-author-ivane-gamkrelidze"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/5874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/users\/939"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/comments?post=5874"}],"version-history":[{"count":4,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/5874\/revisions"}],"predecessor-version":[{"id":7513,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/5874\/revisions\/7513"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media\/3193"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media?parent=5874"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/categories?post=5874"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/tags?post=5874"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/publication-author?post=5874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}